ONE WORLD TRADE CENTER, NEW YORK, NY
Phase 3 Panorama Study Topline Data Readout
Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
Reports Second Quarter 2026 Financial Results and Recent Highlights
Announces Pricing of $700 Million Upsized Public Offering
Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
Shareholders Approve Amendment to 2025 Equity Incentive Plan
Investor Presentation
Q2
Q1
FY 2024
Q3
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Definitive Additional Information Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Prospectus filed pursuant to Rule 424(b)(7)
Correspondence
Submission Upload